RT Journal Article
T1 Prediagnostic Blood Selenium Status and Mortality among Patients with Colorectal Cancer in Western European Populations.
A1 Baker, Jacqueline Roshelli
A1 Umesh, Sushma
A1 Jenab, Mazda
A1 Schomburg, Lutz
A1 Tjønneland, Anne
A1 Olsen, Anja
A1 Boutron-Ruault, Marie-Christine
A1 Rothwell, Joseph A
A1 Severi, Gianluca
A1 Katzke, Verena
A1 Johnson, Theron
A1 Schulze, Matthias B
A1 Masala, Giovanna
A1 Agnoli, Claudia
A1 Simeon, Vittorio
A1 Tumino, Rosario
A1 Bueno-de-Mesquita, H Bas
A1 Gram, Inger Torhild
A1 Skeie, Guri
A1 Bonet, Catalina
A1 Rodriguez-Barranco, Miguel
A1 Houerta, José María
A1 Gylling, Björn
A1 Van Guelpen, Bethany
A1 Perez-Cornago, Aurora
A1 Aglago, Elom
A1 Freisling, Heinz
A1 Weiderpass, Elisabete
A1 Cross, Amanda J
A1 Heath, Alicia K
A1 Hughes, David J
A1 Fedirko, Veronika
K1 cohort
K1 colorectal cancer
K1 selenium
K1 selenoprotein P
K1 survival
AB A higher selenium (Se) status has been shown to be associated with lower risk for colorectal cancer (CRC), but the importance of Se in survival after CRC diagnosis is not well studied. The associations of prediagnostic circulating Se status (as indicated by serum Se and selenoprotein P (SELENOP) measurements) with overall and CRC-specific mortality were estimated using multivariable Cox proportional hazards regression among 995 CRC cases (515 deaths, 396 from CRC) in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Se and SELENOP serum concentrations were measured on average 46 months before CRC diagnosis. Median follow-up time was 113 months. Participants with Se concentrations in the highest quintile (≥100 µg/L) had a multivariable-adjusted hazard ratio (HR) of 0.73 (95% CI: 0.52-1.02; Ptrend = 0.06) for CRC-specific mortality and 0.77 (95% CI: 0.57-1.03; Ptrend = 0.04) for overall mortality, compared with the lowest quintile (≤67.5 µg/L). Similarly, participants with SELENOP concentrations in the highest (≥5.07 mg/L) compared with the lowest quintile (≤3.53 mg/L) had HRs of 0.89 (95% CI: 0.64-1.24; Ptrend = 0.39) for CRC-specific mortality and 0.83 (95% CI: 0.62-1.11; Ptrend = 0.17) for overall mortality. Higher prediagnostic exposure to Se within an optimal concentration (100-150 µg/L) might be associated with improved survival among CRC patients, although our results were not statistically significant and additional studies are needed to confirm this potential association. Our findings may stimulate further research on selenium's role in survival among CRC patients especially among those residing in geographic regions with suboptimal Se availability.
SN 2227-9059
YR 2021
FD 2021-10-22
LK https://hdl.handle.net/10668/24677
UL https://hdl.handle.net/10668/24677
LA en
DS RISalud
RD Apr 11, 2025